| Name | Title | Contact Details |
|---|---|---|
Mark DePristo |
Founder and Chief Executive Officer | Profile |
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.
BioAssist is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
I.C.H. Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nucryst Pharmaceuticals Corp. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Verséa Health is a diversified global healthcare company engaged in scientific discovery, development and commercialization of innovative products and services intended to diagnose, manage, and treat debilitating diseases.